Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 3521 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: - **ISIS 3521 (aprinocarsen)**, an antisense phosphorothioate oligonucleotide that inhibits the expression of protein kinase C-alpha (PKCα), a serine/threonine kinase implicated in cancer cell proliferation and survival. By binding to the mRNA of PKCα, it leads to RNase-H-mediated degradation and downregulation of this protein[2][5]. - **Carboplatin**, a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells[7]. - **Paclitaxel**, a microtubule-stabilizing agent that disrupts mitosis by preventing microtubule depolymerization, leading to cell cycle arrest and apoptosis[7]. The combination has been studied primarily for advanced solid tumors, especially non-small cell lung cancer (NSCLC), with the rationale that ISIS 3521 may sensitize tumor cells to standard chemotherapies like carboplatin and paclitaxel[8].
- Other names
- ISIS 3521 + carboplatin + paclitaxel
02
Targets
PRKCA (Protein kinase C alpha)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ISIS 3521 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 3521 + carboplatin + paclitaxel.